Literature DB >> 11136955

The pathogenesis of acute pulmonary edema associated with hypertension.

S K Gandhi1, J C Powers, A M Nomeir, K Fowle, D W Kitzman, K M Rankin, W C Little.   

Abstract

BACKGROUND: Patients with acute pulmonary edema often have marked hypertension but, after reduction of the blood pressure, have a normal left ventricular ejection fraction (> or =0.50). However, the pulmonary edema may not have resulted from isolated diastolic dysfunction but, instead, may be due to transient systolic dysfunction, acute mitral regurgitation, or both.
METHODS: We studied 38 patients (14 men and 24 women; mean [+/-SD] age, 67+/-13 years) with acute pulmonary edema and systolic blood pressure greater than 160 mm Hg. We evaluated the ejection fraction and regional function by two-dimensional Doppler echocardiography, both during the acute episode and one to three days after treatment.
RESULTS: The mean systolic blood pressure was 200+/-26 mm Hg during the initial echocardiographic examination and was reduced to 139+/-17 mm Hg (P< 0.01) at the time of the follow-up examination. Despite the marked difference in blood pressure, the ejection fraction was similar during the acute episode (0.50+/-0.15) and after treatment (0.50+/-0.13). The left ventricular regional wall-motion index (the mean value for 16 segments) was also the same during the acute episode (1.6+/-0.6) and after treatment (1.6+/-0.6). No patient had severe mitral regurgitation during the acute episode. Eighteen patients had a normal ejection fraction (at least 0.50) after treatment. In 16 of these 18 patients, the ejection fraction was at least 0.50 during the acute episode.
CONCLUSIONS: In patients with hypertensive pulmonary edema, a normal ejection fraction after treatment suggests that the edema was due to the exacerbation of diastolic dysfunction by hypertension--not to transient systolic dysfunction or mitral regurgitation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136955     DOI: 10.1056/NEJM200101043440103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  135 in total

1.  Heart failure with a normal ejection fraction: treatments for a complex syndrome?

Authors:  Samuel Bernard; Mathew S Maurer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

2.  Diastolic heart failure.

Authors:  Ramachandran S Vasan
Journal:  BMJ       Date:  2003-11-22

Review 3.  Pulmonary hypertension with left-sided heart disease.

Authors:  Marco Guazzi; Ross Arena
Journal:  Nat Rev Cardiol       Date:  2010-10-05       Impact factor: 32.419

4.  The natural history of preclinical diastolic dysfunction: a population-based study.

Authors:  Mark W Vogel; Joshua P Slusser; David O Hodge; Horng H Chen
Journal:  Circ Heart Fail       Date:  2012-01-25       Impact factor: 8.790

5.  Reversing the Cardiac Effects of Sedentary Aging in Middle Age-A Randomized Controlled Trial: Implications For Heart Failure Prevention.

Authors:  Erin J Howden; Satyam Sarma; Justin S Lawley; Mildred Opondo; William Cornwell; Douglas Stoller; Marcus A Urey; Beverley Adams-Huet; Benjamin D Levine
Journal:  Circulation       Date:  2018-01-08       Impact factor: 29.690

Review 6.  Antihypertensive drugs and the heart.

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

7.  Decreased renal function in hypertensive emergencies.

Authors:  U Derhaschnig; C Testori; E Riedmueller; E L Hobl; F B Mayr; B Jilma
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

Review 8.  Diastolic function in hypertension.

Authors:  R A Phillips; J A Diamond
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 9.  Diagnosis of diastolic heart failure.

Authors:  Hidekatsu Fukuta; William C Little
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

10.  Treatment of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.